Posted by Michael Wonder on 10 Mar 2020
Addressing the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU
10 March 2020 - EMA and its partners in the European medicines regulatory network are closely monitoring the potential impact of the outbreak of the novel coronavirus disease (COVID-19) on pharmaceutical supply chains into the European Union (EU).
No reports of current shortages or supply disruptions of medicines marketed in the EU due to this outbreak have been received at this point.
As the public health emergency develops, shortages or disruptions cannot be excluded.
